Protalix BioTherapeutics (PLX) Other Non-Current Liabilities (2011 - 2021)
Protalix BioTherapeutics (PLX) posted quarterly Other Non-Current Liabilities of $38000.0 for Q2 2021, down 69.35% year-over-year from $124000.0 in Q2 2020, and up 46.15% quarter-over-quarter from $26000.0 in Q1 2021.
Protalix BioTherapeutics (PLX) Other Non-Current Liabilities (2011 - 2021) Analysis & Trends
Protalix BioTherapeutics' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $38000.0 for Q2 2021.
- In Q2 2021, Other Non-Current Liabilities fell 69.35% year-over-year to $38000.0; the TTM figure through Jun 2021 stood at $38000.0 (down 69.35% YoY), while the FY2020 annual figure was $51000.0, down 89.98% from the prior year.
- Other Non-Current Liabilities for Q2 2021 stood at $38000.0, up from $26000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $6.2 million in Q3 2018, with the low at $26000.0 in Q1 2021.
- The 5-year median for Other Non-Current Liabilities is $5.1 million (2017), against an average of $2.9 million.
- The sharpest annual moves came in 2017 and 2020: Other Non-Current Liabilities climbed 17.44% in 2017, then slumped 99.14% in 2020.
- Protalix BioTherapeutics' Other Non-Current Liabilities stood at $5.1 million in 2017, then grew by 4.77% to $5.3 million in 2018, then slumped by 90.38% to $509000.0 in 2019, then slumped by 89.98% to $51000.0 in 2020, then retreated by 25.49% to $38000.0 in 2021.
- Business Quant data shows PLX's Other Non-Current Liabilities at $38000.0 in Q2 2021, $26000.0 in Q1 2021, and $51000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 38,000.00 |
| Mar 31, 2021 | 26,000.00 |
| Dec 31, 2020 | 51,000.00 |
| Sep 30, 2020 | 46,000.00 |
| Jun 30, 2020 | 124,000.00 |
| Mar 31, 2020 | 210,000.00 |
| Dec 31, 2019 | 509,000.00 |
| Sep 30, 2019 | 5.37 Mn |
| Jun 30, 2019 | 5.35 Mn |
| Mar 31, 2019 | 5.29 Mn |
| Dec 31, 2018 | 5.29 Mn |
| Sep 30, 2018 | 6.15 Mn |
| Jun 30, 2018 | 5.26 Mn |
| Mar 31, 2018 | 5.17 Mn |
| Dec 31, 2017 | 5.05 Mn |
| Dec 31, 2016 | 4.30 Mn |
| Mar 31, 2012 | 5.62 Mn |
| Dec 31, 2011 | 6.57 Mn |